Rapid Communication SOLICITATION FOR LETTERS OF INTENT Clinical trials Preclinical experiments

CTEP is soliciting for phase 1 combination and phase 2 single-agent clinical trials of E7389, a halichondrin B analogue tubulin polymerization inhibitor. E7389 is being developed by CTEP in collaboration with Eisai Research Institute (Eisai). E7389 is also available for nonclinical studies via the NCI through a cooperative agreement with Eisai. CTEP is specifically interested in experiments that will generate data useful for prioritization of clinical combination studies, mechanism of action studies, and studies to evaluate radiation sensitization.